Replies to post #119245 on Biotech Values

[DewDiligence]

ALNY is presumably going to need either some concrete clinical results in its RNAi pipeline or at least that change in investor sentiment regarding the possibility of future positive clinical results for a rebound in the share price. Do you see either of those as likely?

I don’t know, which is why I threw out the question. I haven’t paid much attention to ALNY in the last couple of years and was surprised to see how far the valuation had fallen in the aftermath of the Roche and NVS decisions not to continue collaborating.

I may listen to a webcast or two to see if ALNY has the makings of a turnaround story. MRK paid $1.1B for Sirna Therapuetics 4.5 years ago, FWIW.